Researchers at the University of California San Diego say they have found the “missing link” in the chemical system that enables animal cells to produce ribosomes, the cell’s so-called protein factories. These factories, which are contained within each cell, manufacture all of the proteins needed to build tissue and sustain life.

The scientists believe that their work, published this week in Genes & Development, will not only force a revision of basic textbooks on molecular biology, but also provide scientists with a better understanding of how to limit uncontrolled cell growth, such as cancer, that might be regulated by controlling the output of ribosomes.

Regarded as life's most important molecular machine, ribosomes have been intensively studied by scientists (the 2009 Nobel Prize in Chemistry, for example, was awarded for studies of its structure and function). But until now researchers had not uncovered all of the details of how the proteins that are used to construct ribosomes are themselves produced.

In multicellular animals such as humans, ribosomes are made up of about 80 different proteins (humans have 79 while some other animals have a slightly different number) as well as four different kinds of RNA molecules. In 1969, scientists discovered that the synthesis of ribosomal RNAs is carried out by specialized systems using two key enzymes: RNA polymerase I and RNA polymerase III. But until now, scientists were unsure if a complementary system was also responsible for the production of the 80 proteins that make up the ribosome.

That's essentially what the UC San Diego researchers headed by Jim Kadonaga, Ph.D., a professor of biology, set out to examine. What they found was a specialized system that allows ribosomal proteins themselves to be synthesized by the cell.

“We found that ribosomal proteins are synthesized via a novel regulatory system with the enzyme RNA polymerase II and a factor termed TRF2,” explained Dr. Kadonaga. “For the production of most proteins, RNA polymerase II functions with a factor termed TBP, but for the synthesis of ribosomal proteins, it uses TRF2. The discovery of this specialized TRF2-based system for ribosome biogenesis provides a new avenue for the study of ribosomes and its control of cell growth, and should lead to a better understanding and potential treatment of diseases such as cancer.”

Previous articleRoche, Inception Sciences, and Versant Partner on Therapies for MS
Next articleCancer Genetics Buys Gentris for Up to $6.25M